Financials data is unavailable for this security.
View more
Year on year Vita Life Sciences Ltd grew revenues 10.88% from 66.89m to 74.16m while net income improved 28.18% from 7.08m to 9.08m.
Gross margin | 58.48% |
---|---|
Net profit margin | 11.90% |
Operating margin | 15.48% |
Return on assets | 15.37% |
---|---|
Return on equity | 21.37% |
Return on investment | 21.18% |
More ▼
Cash flow in AUDView more
In 2023, Vita Life Sciences Ltd increased its cash reserves by 57.00%, or 8.94m. The company earned 12.98m from its operations for a Cash Flow Margin of 17.51%. In addition the company used 660.00k on investing activities and also paid 2.88m in financing cash flows.
Cash flow per share | 0.1804 |
---|---|
Price/Cash flow per share | 13.35 |
Book value per share | 0.865 |
---|---|
Tangible book value per share | 0.8646 |
More ▼
Balance sheet in AUDView more
Current ratio | 2.96 |
---|---|
Quick ratio | 2.18 |
Total debt/total equity | 0.0088 |
---|---|
Total debt/total capital | 0.0088 |
More ▼
Growth rates in AUD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 50.00% and 26.54%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg) | 2.57% |
---|---|
Div growth rate (5 year) | 19.14% |
Payout ratio (TTM) | 50.43% |
EPS growth(5 years) | 30.17 |
---|---|
EPS (TTM) vs TTM 1 year ago | 26.91 |
More ▼